MannKind Corporation  

(Public, NASDAQ:MNKD)   Watch this stock  
Find more results for Matthew Kent�
5.73
-0.21 (-3.54%)
After Hours: 5.70 -0.03 (-0.52%)
Mar 5, 5:13PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.61 - 5.94
52 week 3.80 - 11.48
Open 5.93
Vol / Avg. 7.31M/7.19M
Mkt cap 2.42B
P/E     -
Div/yield     -
EPS -0.51
Shares 408.84M
Beta 1.02
Inst. own 25%
May 18, 2015
MannKind Annual Shareholder Meeting (Estimated) Add to calendar
May 11, 2015
Q1 2015 Mannkind Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Feb 25, 2015
Mannkind Corp at RBC Healthcare Conference
Feb 24, 2015
Q4 2014 Mannkind Corp Earnings Call - Webcast
Feb 24, 2015
Q4 2014 Mannkind Corp Earnings Release
Jan 14, 2015
Mannkind Corp at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -37.42% -60.75%
Return on average equity - -
Employees 265 -
CDP Score - -

Address

28903 North Avenue Paine
VALENCIA, CA 91355
United States - Map
+1-661-7755300 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

MannKind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. The Company�s product candidate is AFREZZA which is an ultra rapid-acting insulin that is intended to improve glycemic control in adults with type 1 or type 2 diabetes. AFREZZA is absorbed into the bloodstream more quickly than subcutaneously injected rapid acting insulin analogs and regular human insulin. The time action profile of AFREZZA mimics the early phase insulin response observed in healthy normal individuals after a meal, which is characteristically absent in patients with type 2 diabetes. The Company�s subsidiaries are AlleCure and CTL.

Officers and directors

Alfred E. Mann Chairman of the Board
Age: 88
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Hakan S. Edstrom President, Chief Executive Officer, Chief Operating Officer, Director
Age: 65
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Matthew J. Pfeffer CPA Corporate Vice President and Chief Financial Officer
Age: 56
Bio & Compensation  - Reuters
Juergen A. Martens Ph.D. Corporate Vice President - Technical Operations, Chief Technical Officer
Age: 58
Bio & Compensation  - Reuters
David B. Thomson Ph.D., J.D. Corporate Vice President, General Counsel, Corporate Secretary
Age: 47
Bio & Compensation  - Reuters
Diane M. Palumbo Corporate Vice President - Human Resources
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Kent Kresa Lead Independent Director
Age: 76
Bio & Compensation  - Reuters
Ronald J. Consiglio Independent Director
Age: 70
Bio & Compensation  - Reuters
Michael A. Friedman M.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
David H. MacCallum Independent Director
Age: 77
Bio & Compensation  - Reuters